BridgeBio price target raised to $46 from $42 at Citi

Citi raised the firm’s price target on BridgeBio to $46 from $42 and keeps a Buy rating on the shares post the Q4 report. The analyst says recent updates to a competitor Amvuttra’s pivotal trial do not alter Citi’s view on acoramidis’ competitive positioning. While Amvuttra will likely lead the TTR space, acoramidis could garner a meaningful share, the analyst tells investors in a research note.